Board of Directors approved the Company’s 2018 individual and consolidated financial statements

Announcement of the resolution of the treasury shares and the establishment of the base date for capital reduction by board of directors
March 8, 2019
Change of accountant due to internal adjustment of the accounting firm
March 8, 2019
  1. Date of occurrence of the event: Mar 8, 2019
  2. Company name: OBI Pharma Inc.
  3. Relationship to the Company (please enter “head office” or subsidiaries”): Head office
  4. Reciprocal shareholding ratios: N/A
  5. Cause of occurrence:
    From the 2018 Individual/Consolidated Financial Statement:
    Individual Financial Statement:
    Operating loss :(1,300,667) thousand dollars
    Total comprehensive loss for the period :(1,224,428) thousand dollars
    Loss Per Share (in dollars) :( 7.06) dollars

    Consolidated Financial Statement:
    Operating loss :(1,427,683) thousand dollars
    Total comprehensive loss for the period :(1,251,780) thousand dollars
    Loss Per Share (in dollars) :( 7.06) dollars

  6. Countermeasures: N/A
  7. Any other matters that need to be specified: None